Real-World Comparison of Clopidogrel With Ticagrelor and Prasugrel in Patients With Chronic Coronary Disease Who Underwent Atherectomy

Am J Cardiol. 2024 Apr 15:217:1-4. doi: 10.1016/j.amjcard.2024.02.006. Epub 2024 Feb 23.

Authors

Mahin R Khan¹, Anoop N Koshy¹, Richard Tanner¹, Serdar Farhan¹, Manish Vinayak¹, Ali Farooq¹, Samantha Sartori¹, Yihan Feng¹, Alessandro Spirito¹, Ayush Arora¹, Vishal Dhulipala¹, Vishal Kapur¹, Javed Suleman¹, Raman Sharma¹, Roxana Mehran¹, Annapoorna Kini¹, Samin K Sharma²

Affiliations

¹ The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
² The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: [email protected].

PMID: 38401658
DOI: 10.1016/j.amjcard.2024.02.006

No abstract available

Keywords: atherectomy; calcified lesions; chronic coronary disease; complex PCI; potent antiplatelets.

MeSH terms

Acute Coronary Syndrome*
Atherectomy
Clopidogrel / therapeutic use
Coronary Disease*
Heart Diseases*
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors / therapeutic use
Prasugrel Hydrochloride / therapeutic use
Purinergic P2Y Receptor Antagonists / therapeutic use
Ticagrelor / therapeutic use
Treatment Outcome

Substances

Clopidogrel
Ticagrelor
Prasugrel Hydrochloride
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists